loader image
Saturday, June 28, 2025
77.5 F
McAllen
We Welcome your Press Release
- Advertisement -

Post-Exposure Prophylactic Use of Monoclonal Antibodies

Translate to Spanish or other 102 languages!

The study entails a single treatment with REGEN-COV monoclonal antibody which is either infused intravenously or administered subcutaneously. Image for illustration purposes.
The study entails a single treatment with REGEN-COV monoclonal antibody which is either infused intravenously or administered subcutaneously. Image for illustration purposes.

Mega Doctor News

- Advertisement -

Edinburg, TX – Monoclonal antibody infusion has been used quite extensively in treating mild-moderated SARS-CoV-2 infection. The primary objective of this treatment is to prevent the progression of disease to a severe stage requiring hospitalization. At DHR Health and DHR Health Institute for Research & Development, we have infused REGEN-COV monoclonal antibody to over 500 patients with mild-moderate SARS-CoV-2 infection with very satisfactory outcome. This included adults, children and pregnant women who were at high risk for developing severe COVID-19 disease.

“We are embarking on a new project that is both FDA and IRB-approved to infuse monoclonal antibodies to asymptomatic high-risk individuals who are COVID-19 negative but have been exposed to a COVID-19 positive patient” said Sohail Rao, MD, MA, DPhil, President & CEO, DHR Health Institute for Research & Development. “The purpose of this initiative is to prevent the development of SARS-CoV-2 infection in qualified adults and children 12 years of age or over who are exposed to a COVID-19 positive patient for at least 15 minutes in a 24-hour period”.

The study entails a single treatment with REGEN-COV monoclonal antibody which is either infused intravenously or administered subcutaneously. To learn more about who would qualify for this treatment, please visit this website:https://dhrresearch.org/wp-content/uploads/2021/08/CHECKLIST-08-08-2021-1.pdf  or call the post-exposure prophylaxis hotline (956) 362-2357 (9:00 a.m. – 5:00 p.m.; M-F) for more information.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS Edinburg Nominated for Most Beautiful Hospitals in the U.S. Contest

Mega Doctor News STHS Edinburg is nominated in Soliant’s Most Beautiful Hospitals...

Study Reveals Mechanisms Behind Common Mutation and Prostate Cancer

Mega Doctor News By Michigan Medicine - University of Michigan Newswise - A new study...

How Horses Are Helping Parkinson’s Patients 

Teas Border Business By Paul Schattenberg / Texas A&M AgriLife For children, veterans...

DHR Health Becomes RGV’s First and Only Comprehensive Multiple Sclerosis Center

Mega Doctor News EDINBURG, Texas - DHR Health is proud to announce that...
- Advertisement -
×